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Abstract The enhancement of re-endothelialisation is a
critical therapeutic option for repairing injured blood ves-
sels. Endothelial progenitor cells (EPCs) are the major
source of cells that participate in endothelium repair and
contribute to re-endothelialisation by reducing neointima
formation after vascular injury. The over-expression of the
inhibitor of differentiation or DNA binding 1 (Id1) sig-
niﬁcantly improved EPC proliferation. This study aimed to
investigate the effects of Id1 on the phosphatidylinositol-3-
kinase (PI3K)/Akt/nuclear factor kappa B (NFjB)/survivin
signalling pathway and its signiﬁcance in promoting EPC
proliferation in vitro. Spleen-derived EPCs were cultured
as previously described. Id1 was presented at low levels in
EPCs, and was rapidly up-regulated by stimulation with
vascular endothelial growth factor. We demonstrated that
transient transfection of Id1 into EPCs activated the PI3K/
Akt/NFjB/survivin signalling pathway and promoted EPC
proliferation. The proliferation of EPCs was extensively
inhibited by silencing of endogenous Id1, and knockdown
of Id1 expression led to suppression of PI3K/Akt/NFjB/
survivin signalling pathway in EPCs. In addition, blockade
by the PI3K-speciﬁc inhibitor LY294002, Akt inhibitor, the
NFjB inhibitor BAY 11-7082, the survivin inhibitor Cur-
cumin, or the survivin inhibitor YM155 reduced the effects
of Id1 transfection. These results suggest that the Id1/PI3K/
Akt/NFjB/survivin signalling pathway plays a critical role
in EPC proliferation. The Id1/PI3K/Akt/NFjB/survivin
signalling pathway may represent a novel therapeutic target
in the prevention of restenosis after vascular injury.
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Introduction
Atherosclerosis is the pathological basis of cardiovascular
disease, and the progression from the onset of atheroscle-
rosis to cardiovascular disease can take decades [1].
Endothelial damage is a major contributing factor to ath-
erosclerosis and post-angioplasty restenosis [2, 3]. The
enhancement of re-endothelialisation is a critical thera-
peutic option for repairing injured blood vessels [4, 5]. The
number and function of circulating endothelial progenitor
cells (EPCs) are inversely correlated with risk factors for
coronary artery disease and are predictive of the occurrence
of cardiovascular events and death [6, 7]. EPCs can home
to sites of tissue injury, differentiate into mature ECs, and
participate in re-endothelialisation after vascular injury
[8–11]. Increasing evidence suggests that the circulation of
EPCs may be an endogenous repair mechanism for main-
taining the integrity of the endothelial monolayer by
replacing denuded segments of the artery [12–14]. The
migration and proliferation of EPCs are the key mecha-
nisms of vascular development [15]. These mechanisms are
regulated by various processes and signals. However, the
regulatory mechanisms of the biological properties of
EPCs remain unclear. Recent studies demonstrated that
tumour-induced expression of inhibitor of differentiation or
DNA binding 1 (Id1) in EPCs and conditional Id1 sup-
pression impaired the mobilisation of EPCs [16].
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loop–helix (HLH) proteins. Increased Id1 expression has
been implicated in regulating the growth, proliferation,
migration, and differentiation of cells [17]. Moreover, Id1
has been demonstrated to promote the proliferation and
survival of bone marrow- and spleen-derived EPCs [18,
19]. However, the signalling mechanisms responsible for
Id1-mediated EPC functions have not been addressed. It
has been reported that Id1 is possibly linked to the phos-
phatidylinositol-3-kinase (PI3K)/Akt, PI3K/Akt/nuclear
factor kappa B (NFjB), and NFjB/survivin pathways in
many types of cancer cells [20–23]. Several studies have
demonstrated that PI3K is necessary for Id1-mediated cell
proliferation and survival [20, 22]. One of the crucial
downstream targets of PI3K is the serine/threonine kinase
Akt, which is recruited to the membrane by direct binding
of its pleckstrin homology domain to the PI3K-produced
phosphatidylinositol 3,4,5-trisphosphate. Activated Akt can
phosphorylate a number of proteins including glycogen
synthase kinase-3b (GSK-3b), 6-phosphofructo-2-kinase,
and IjB. The phosphorylation of IjB frees NFjB and
allows it to translocate to the nucleus to bind and subse-
quently activate target genes. Survivin, a prominent anti-
cancer target, is ubiquitously expressed in a plethora of
cancers. Pertaining to recent studies, the modulation of
survivin is critically regulated by its interaction with
prominent cell-signalling pathways such as the PI3K/Akt,
mTOR, ERK, and NFjB pathways [22, 24, 25]. A recent
study indicated that the expression of survivin is under the
control of NFjB[ 22]. However, the mechanism responsi-
ble for Id1/PI3K/Akt/NFjB/survivin pathway activation in
EPCs is largely unknown.
In this study, we hypothesised that Id1 is linked to the
proliferation of EPCs via the regulation of the PI3K/Akt/
NFjB/survivin pathway. Our in vitro data demonstrated
that Id1 up-regulated survivin via a PI3K/Akt/NFjB-
dependent mechanism, contributing to the proliferation of
EPCs.
Materials and methods
Study approval
All procedures were performed in accordance with the
guidelines of the Animal Research Committee of the Third
Military Medical University, Chongqing, China.
Animals
Sprague–Dawley rats (1–2 months old, 180–200 g weight)
were obtained from the Experimental Animal Centre of
Third Military Medical University.
Isolation and characterisation of EPCs
The culture and characterisation of EPCs were performed
according to previous methods used by our research group
[26]. Brieﬂy, total spleen-derived mononuclear cells were
isolated by density gradient centrifugation (Lymphoprep
1.083, Tianjin, China) at 4009g for 20 min. After puriﬁca-
tion using three washing steps, the cells were plated on
gelatine-coated cell culture ﬂasks and re-suspended in low-
glucose Dulbecco’s modiﬁed Eagle’s medium (DMEM-L)
supplemented with 10% foetal calf serum (FCS) and 10 ng/
ml vascular endothelial growth factor (VEGF). The cells
were incubated at 37C under an atmosphere of 5% CO2.
Twenty-fourhourslater,non-adherentcellsweretransferred
to a new ﬂask to remove adherent hematopoietic cells and
mature ECs. Another 48 h later, non-attached cells were
removed, and the adherent cells were cultured continuously.
Only adherent cells were used in further experiments. The
medium was refreshed every 3 days. For characterisation,
the cells were incubated with Dil-Ac-LDL (10 mg/ml) for
4 h, ﬁxed with 4% paraformaldehyde and then incubated
with FITC-labelled lectin (UEA-1, 10 mg/ml) for 1 h.
Finally, the cells were incubated with 40,6-diamidino-2-
phenylindole (DAPI, 1 lg/ml) for 5 min. Triple-stained
cells positive for Dil-Ac-LDL, lectin and DAPI were iden-
tiﬁed as EPCs. Additionally, ﬂow cytometric cell sorting
(FACS) analysis was performed using antibodies against rat
CD133, CD34, CD45, VEGFR-2, and the corresponding
isotype control antibodies (Bios, Beijing, China).
Reagents
The anti-Id1 antibody was purchased from Abcam; anti-p-
PI3K, anti-PI3K, anti-p-Akt, anti-Akt, anti-p-IjB, anti-
survivin, and anti-NFjB/p65 antibodies were obtained
from Cell Signaling Technology. FCS was obtained from
HyClone. Medium and supplements were purchased from
Gibco BRL. LY294002, BAY 11-7082, Akt inhibitor, and
Curcumin were obtained from Santa Cruz Biotechnology.
Recombinant adenoviral vectors expressing Id1
An adenovirus (Ad) vector expressing Id1 or CCN1 and an
Ad-encoding green ﬂuorescent protein (GFP; Ad-GFP)
were used as controls and were previously created by our
group [27]. The EPCs were transfected with Ad-Id1,
Ad-CCN1, or Ad-GFP for 48 h and used in the experiments.
Small interfering RNA-mediated silencing of Id1
expression
Transient silencing of Id1 was accomplished by transfec-
tion with small interfering RNAs (si-Id1). The selected
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123siRNA duplex sequences speciﬁcally targeted rat Id1 (rId1,
GenBank accession number NM_012797), and showed no
homology to any other sequences by a blast search. The
si-Id1 target site is 50-ttgtcgcgaccgccggaggcc-30 from 380
to 400 bp. A non-silencing control (si-CON) sequence was
designed according to the sequence of a negative control.
Transfection of si-Id1 was carried out using Lipofectamine
2000 reagent with a molar ratio between DNA and lipid of
about 1:3. Forty-eight hours after transfection, cells were
collected and used for functional assays.
Western blot analysis
Proteins from cell lysates were measured using the Bradford
method. Equal amounts of the soluble fractions were sepa-
rated by a 10–15% SDS-PAGE gel and electrophoretically
transferred onto a polyvinylidene diﬂuoride membrane. The
membranes were blocked with 5% non-fat milk. The mem-
braneswereallowedtoreactwithaprimaryantibody,andthe
detection of speciﬁc proteins was performed by enhanced
chemiluminescence following the manufacturer’s instruc-
tions. The densitometric signals were quantiﬁed by Quantity
One.
Enzyme-linked immunospeciﬁc assay (ELISA)
Protein levels of VEGF in the cell supernatants were
determined by ELISA kit (R&D Systems), according to the
manufacturer’s instructions. Samples were measured in
triplicate and were properly diluted to ensure that measured
values were within the concentration range of the standard
curve.
Cell proliferation assay
The EPCs were trypsinised from the cultures and placed into
ﬁbronectin-coated 96-well plates (2 9 10
6 cells/ml). Cell
proliferation was measured by the 3-(4, 5-dimethylthiazol-2-
yl)-5(3-carboxymethoxyphenyl)-2-(4-sulfopheny)-2H-tet-
razolium (MTS) assay according to the manufacturer’s
protocol. Before reading the optical density (490 nm), 20 ll
of MTS solution was added to each well. All groups of
experiments were performed in triplicate.
Statistical analysis
Data from at least three independent experiments are
expressed as the mean ± SD. SPSS 18.0 software was
used for statistical analysis. Groups of data were com-
pared with ANOVA followed by a Tukey’s multiple
comparison tests. P values \0.05 were taken to be sta-
tistically signiﬁcant.
Results
Characterisation of spleen-derived EPCs
After 5–7 days in culture, the attached cells were analysed
using immunoﬂuorescence and FACS. Immunocytochemis-
trystainingdemonstratedthatthemajorityofthecells([90%)
stainedpositivelyforDil-Ac-LDL,lectin,andDAPI(Fig. 1a)
and expressed endothelial/stem cell markers including
CD133, CD34, and VEGFR-2 but not CD45 (Fig. 1b).
Id1 expression is up-regulated in EPCs in the presence
of VEGF
We then investigated the expression of Id1 in primary
EPCs. As shown in Fig. 2a, Id1 was present at fairly low
levels in quiescent EPCs, but was rapidly up-regulated
upon stimulation with serum and VEGF. And, the prolif-
eration of EPCs was signiﬁcantly accelerated after stimu-
lation with VEGF compared with control group (Fig. 2b).
Given the signiﬁcant correlation between Id1 and VEGF,
we then investigated whether there is an interaction
between Id1 and VEGF in EPCs. In this study, we con-
structed recombinant Ad, Ad-Id1, and transduced it into
EPCs to examine the effect on VEGF at protein levels. By
ELISA, there was a signiﬁcant increase in VEGF protein
secretion in Id1 transfectants when compared with the
control (Fig. 2c). These results indicated an important
relationship between Id1 and VEGF in EPCs.
Id1 is involved in the effect of the PI3K/Akt/NFjB/
survivin pathway on EPC proliferation
Id1 has an important role in the proliferation, differentia-
tion, and migration of cells. Id1 activates the PI3K/Akt,
PI3K/Akt/NFjB, and NFjB/survivin signalling pathways,
and protects cancer cells from apoptosis in vitro [20–22].
We previously observed that Id1 promoted EPC prolifer-
ation [18]. To clarify whether there is any association
between Id1 and PI3K/Akt/NFjB/survivin signalling in the
regulation of EPC proliferation, Ad-Id1 or Ad-GFP was
transiently transfected into EPCs. As shown in Fig. 3a,
there was increased Id1, p-PI3K, p-Akt, p-IjB, and survi-
vin expression and increased nuclear translocation of
NFjB/p65 in EPCs transfected with Ad-Id1. EPCs trans-
fected with Ad-Id1 and Ad-GFP were subsequently sub-
jected to the MTS assay separately to examine their
proliferation. The proliferation of EPCs transfected with
Ad-Id1 was enhanced to about 200% compared with that of
Ad-GFP transfected EPCs (P\0.05) (Fig. 3c).
Although the over-expression of exogenous Id1 directly
enhanced EPC proliferation, the role of endogenous Id1
was not fully elucidated. Because the basal expression of
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123Id1 in quiescent EPCs was barely detectable, and it was
dramatically increased in response to stimulations such as
serum and VEGF, we therefore used siRNA fragments to
silence the Id1 gene in EPCs, and the culture medium
containing 20% FCS and 10 ng/ml VEGF was used as
stimulation. Instruction of si-Id1 caused an approximate
50% loss of Id1, p-PI3K, p-Akt, p-IjB, and survivin
expressionanddecreasednucleartranslocationofNFjB/p65
Fig. 2 Id1 expression is up-regulated in EPCs in the presence of
VEGF. a Protein level of Id1 in the EPCs stimulated with serum and
VEGF using western blot analysis. Values are presented as the
percentage of GAPDH (serum and VEGF free, null treatment). b The
proliferation of EPCs was examined by MTS assays. The proliferation
of EPCs was signiﬁcantly accelerated after stimulation with VEGF
compared with the control. c Supernatants from EPCs transfected
with Ad-Id1 were collected and subjected to ELISA analysis, using
VEGF speciﬁc kits. Expression of VEGF was increased by Ad-Id.
The values are expressed as the mean ± SD.
#P\0.05 versus control
Fig. 1 The isolation and
characterisation of EPCs.
a EPCs stained positive for Dil-
Ac-LDL, lectin, and DAPI
(magniﬁcation 9400). b FACS
analysis of primary EPCs
cultured for 5–7 days in low-
glucose DMEM supplemented
with 10% FCS. Cells labelled
with ﬂuorescent antibodies
CD133, CD34, CD45, and
VEGFR-2 are shown in the
areas to the right in each box.
The left area in each box
represents the corresponding
negative control labelling, and
the line denotes a positive gate.
The numbers are the percentage
of positive cells
138 Mol Cell Biochem (2012) 363:135–145
123in EPCs as measured by western blot (Fig. 3b). And signif-
icantly, the EPCs exhibited a decrease in cell proliferation
compared with the control group (Fig. 3d). Thus, these
results indicated that knockdown of endogenous Id1 signif-
icantly reduced the proliferation of EPC, suggesting an
important role in EPCs of endogenous Id1.
Taken together, our results indicated that Id1 activated
the PI3K/Akt/NFjB/survivin signalling pathway in the
regulation of EPC proliferation.
PI3K blockade reduces Id1-induced Akt/NFjB/survivin
activation
It has been documented that Id1 activates Akt through the
PI3K pathway. To investigate the role of PI3K in Id1-
induced EPC proliferation and determine whether PI3K is
involved in the induction of Akt/NFjB/survivin in the Id1-
over-expressing EPCs, cells transfected with Ad-Id1 were
incubated with a PI3K-speciﬁc inhibitor, LY294002. The
MTSassayandwesternblotanalysiswereperformedat48 h
after transfection. As shown in Fig. 4a, treatment with
LY294002 attenuated Id1-induced p-PI3K, p-Akt, p-IjB,
and survivin expression as well as decreased the nuclear
translocationofNFjB/p65inEPCstransfectedwithAd-Id1.
This result indicated the signiﬁcance of PI3K in the activa-
tion of the Akt/NFjB/survivin pathway. The proliferation
effect was strongly inhibited by the PI3K-speciﬁc inhibitor
LY294002 compared with the proliferation in untreated
Ad-Id1-transfectedEPCs(Fig. 4b).Thesedatasuggestedthat
theeffectofPI3KinhibitiononId1-inducedEPCproliferation
may be due to reduced Akt/NFjB/survivin activity.
Id1-induced nuclear translocation of NFjB/p65 is
mediated through PI3K/Akt signalling
NFjB is a ubiquitously expressed transcription factor that
has been reported to be downstream of the PI3K/Akt
pathway. After ﬁnding that Id1 activated PI3K, Akt, and
Fig. 3 The inﬂuence of Id1
over-expression and silencing
on the activation of the PI3K/
Akt/NFjB/survivin signalling
pathway and proliferation of
EPCs. a, b Left proteins(Id1,
p-PI3K, p-Akt, p-IjB, survivin,
and nuclear NFjB/p65) from
EPCs transfected with Ad-Id1
or si-Id1 were collected and
subjected to western blot
analysis. Right densitometric
analysis of Id1, p-PI3K, p-Akt,
p-IjB, NFjB/p65 (nuclear), and
survivin protein expression
levels were determined by
Quantity One. c, d The
proliferation of EPCs was
examined by MTS assays. The
proliferation of EPCs
transfected with Ad-Id1 was
enhanced to about 200% as
compared with that of Ad-GFP-
transfected EPCs. Whereas
knockdown of endogenous Id1
signiﬁcantly reduced the
proliferation of EPCs compared
with the control group. The
results are expressed as the
mean ± SD.
#P\0.05 versus
control
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123NFjB, we wished to demonstrate that PI3K/Akt is required
for the Id1-mediated activation of NFjB. After incubation
with an Akt-speciﬁc inhibitor, we measured the nuclear
translocation of NFjB/p65 and survivin expression in cells
transfected with Ad-Id1 using western blot analysis. As
shown in Fig. 4a, inhibition of Akt activity in Ad-Id1-
transfected EPCs by Akt inhibitor reduced the expression
of p-Akt, p-IjB, and survivin as well as decreased the
nuclear translocation of NFjB/p65. Cell proliferation
measured by the MTS assay in the Akt-speciﬁc inhibitor
group was signiﬁcantly lower than that in the Ad-Id1 group
(Fig. 4b). These results suggested that NFjB activation
was mediated through the PI3K/Akt signalling pathway.
NFjB inhibition can reduce Id-induced
survivin activation
Because NFjB and survivin are co-expressed in many
types of cancer cells that are induced to proliferate by Id1,
we postulated that Id1 might control the expression of
survivin in EPCs via NFjB. To test this hypothesis, EPCs
transfected with Ad-Id1 were treated with the NFjB
inhibitor BAY 11-7082, which resulted in attenuated
phosphorylation of IjB and nuclear translocation of NFjB/
p65 without effects on PI3K/Akt activity (Fig. 4a).
Simultaneously, Id1-induced survivin expression was
abrogated by BAY 11-7082 as judged by western blot
analysis (Fig. 4a). Interestingly, treatment with the NFjB
inhibitor decreased the proliferation of EPCs compared
with the proliferation of EPCs transfected with Ad-Id1
(Fig. 4b).These results suggested that survivin may be a
downstream effector molecule of NFjB that could mediate
this process.
Survivin inhibition impairs Id1-induced EPC
proliferation
To determine whether survivin had an effect on EPC pro-
liferation, rat spleen-derived EPCs were cultured for in
vitro experiments. The survivin inhibitor Curcumin and
Fig. 4 Blockage of the PI3K/Akt/NFjB/survivin signalling pathway
abrogated Id1-induced EPC proliferation. a Left western blot dem-
onstrating that blockade by the PI3K-speciﬁc inhibitor LY294002 and
Akt inhibitor reduced p-Akt, p-IjB, survivin expression, and NFjB/
p65 nuclear translocation in EPCs transfected with Ad-Id1. Treatment
with the NFjB inhibitor BAY 11-7082 signiﬁcantly decreased the
nuclear translocation of NFjB subunit p65 but did not affect PI3K/
Akt activity. Treatment with the survivin inhibitor Curcumin or
YM155 signiﬁcantly decreased the expression of survivin but did not
affect PI3K/Akt/NFjB activity. Right densitometric analysis of Id1,
p-PI3K, p-Akt, p-IjB, NFjB/p65 (nuclear), and survivin protein
expression levels were determined by Quantity One. b The prolifer-
ation of EPCs was examined by MTS assays. The proliferation of
EPCs was enhanced in the presence of Ad-Id1. The effect was
damped in the presence of the PI3K-speciﬁc inhibitor LY294002, Akt
inhibitor, the NFjB inhibitor BAY 11-7082, the survivin inhibitor
Curcumin, or the survivin inhibitor YM155. The values are expressed
as the mean ± SD.
#P\0.05 versus Ad-Id1
140 Mol Cell Biochem (2012) 363:135–145
123YM155 was separately added to EPCs transfected with
Ad-Id. The basal and induced survivin levels were detected
in vitro by western blot analysis. Interestingly, treatment
with the survivin inhibitor Curcumin and YM155 signiﬁ-
cantly decreased the expression of survivin but did not
affect PI3K/Akt/NFjB activity (Fig. 4a). Concomitantly,
the inhibition of survivin by Curcumin and YM155 sig-
niﬁcantly suppressed the proliferation of EPCs (Fig. 4b).
These results demonstrated that survivin might be an
important effector molecule that could promote EPC pro-
liferation in vitro.
The effect of PI3K/Akt inhibition on the expression
of Id1 in EPCs
In the present study, we observed that Id1 activated the
PI3K/Akt signalling pathway in the regulation of EPC
proliferation. In addition, observations from others showed
that inhibition of PI3K/Akt down-regulated the expression
level of Id1 and reduced EPCs functions [23]. Therefore,
we concluded that there is an interaction between Id1
and PI3K/Akt signalling pathway in EPCs. To test this
hypothesis, EPCs transfected and not transfected with Ad-
Id1 were separately incubated with PI3K/Akt signalling
inhibitor LY294002. As shown in Fig. 5a, Id1 and p-Akt
expression were strongly decreased by LY294002 in EPCs
without exogenous Id1 transfection. However, inhibition
of PI3K/Akt activity in Ad-Id1-transfected EPCs by
LY294002 reduced the expression of p-Akt only but not
Id1 (Fig. 5b). These results indicated that there was an
important interaction between PI3K/Akt and endogenous
Id1 in EPCs, which might ensemble contribute to the EPC
proliferation.
Impact of Id1 on the effects of CCN1 and p21
Recent studies have indicated that Id1 expression is
involved in the expression of CCN1, and p21, thereby
regulating EPC proliferation and the re-endothelialisation
[19, 27]. To investigate the role of CCN1, and p21, in Id1-
induced EPC proliferation and determine whether Id1 is
involved in the expression of CCN1, and p21, in EPCs, the
MTS assay and western blot analysis were performed. As
shown in Fig. 6a, a 50% decrease in protein level of Id1
was detected in response to Ad-CCN1. Interestingly,
cotransfection with Ad-CCN1 decreased the proliferation
of EPCs compared with the proliferation of EPCs trans-
fected with Ad-Id1 (Fig. 6b). These data showed that,
potently, CCN1 mediated the effect of Id1 on EPC pro-
liferation, but the exact mechanism remains to be fully
understood. In order to clarify whether Id1 is involved in
the expression of p21, Ad-Id1 and si-Id1 were performed.
As shown in Fig. 6c, there was decreased p21 expression in
EPCs transfected with Ad-Id1, and instruction of si-Id1
extensively improved p21 expression by western blot
(Fig. 6d). Taken together, these results demonstrated that
Id1 expression was involved in the expression of CCN1,
and p21, thereby regulating EPC proliferation in vitro.
Discussion
Our present results demonstrated that Id1 stimulated cell
proliferation; up-regulated p-PI3K, p-Akt, p-IjB, and sur-
vivin expression; and promoted the nuclear translocation of
NFjB/p65 in EPCs. These effects were abrogated in the
presence of the PI3K-speciﬁc inhibitor LY294002, the Akt
Fig. 5 The effects of PI3K/Akt
inhibition on the expression of
Id1 in EPCs. a Id1 and p-Akt
were strongly decreased by
PI3K/Akt signalling inhibitor
LY294002 in EPCs without
exogenous Id1 transfection. The
values are expressed as the
mean ± SD.
#P\0.05 versus
control. b Inhibition of PI3K/
Akt activity in Ad-Id1-
transfected EPCs by LY294002
reduced the expression of p-Akt
only but not Id1. The results are
expressed as the mean ± SD.
#P\0.05 versus Ad-Id1
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inhibitor Curcumin, and the survivin inhibitor YM155.
Simultaneously, knockdown of endogenous Id1 signiﬁ-
cantly reduced the proliferation of EPCs, and led to sup-
pression of PI3K/Akt/NFjB/survivin signalling pathway in
EPCs. These results demonstrated that the proliferation of
EPCs is mediated through the Id1/PI3K/Akt/NFjB/survi-
vin signalling pathway.
Id1 is an important subfamily member of the HLH
transcriptional factor family. Id1 proteins are essential for
cell cycle progression in some cell lines, acting as positive
regulators of cell proliferation. Recent studies demon-
strated that Id1 plays an important role in the regulation of
cell proliferation and survival in human cancers [17, 28]. In
a previous study, we also identiﬁed that Id1 has a critical
role in regulating the proliferation of EPCs [18]. Here, we
showed that Id1 was present at a fairly low level in qui-
escent EPCs, but was rapidly up-regulated upon stimula-
tion with VEGF. The proliferation of EPCs was extensively
improved after stimulation with VEGF. However, the
mechanism responsible for Id1 signalling pathway activa-
tion in EPCs is largely unknown. The proliﬁc function of
Id1 may involve multiple signalling pathways. First, pro-
angiogenic surface proteins such as b4 integrin ﬁbroblast
growth factor receptor-1, and metalloprotease-2, which
were attributed to the proliferation of EPCs during
re-endothelialisation after vascular injury, have been sug-
gested to be downstream molecules of Id1 [18, 23]. Sec-
ond, the growth-promoting function of Id1 also involves
the activation of the mitogen-activated protein kinase and
mouse double minute-2 signalling pathway in many types
of cancer cells [17, 28, 29]. Third, studies have reported
that the SDF1 receptor CXCR4 is regulated by Id1 in T
cells, and the SDF1/CXCR4 interaction plays an important
role in the regulation of EPC proliferation [30].
Recent studies have indicated that Id1 is linked to the
survival of many types of human cancers via its regulation
of the PI3K/Akt, PI3K/Akt/NFjB, and NFjB/survivin
signalling pathways following the initial effects on cellular
proliferation [20–22, 31]. The transfection of head and
neck squamous cell carcinoma cells with Id1 in vitro
induced the phosphorylation of Akt (p-Akt) via PI3K and
increased the expression of survivin via NFjB. Addition-
ally, inhibiting Id1 expression in many types of cells using
short interfering RNA (siRNA) signiﬁcantly reduced PI3K/
Akt and NFjB signalling pathways expression. However,
the mechanism responsible for Id1/PI3K/Akt/NFjB/survi-
vin activation in EPCs is incompletely understood.
Pertaining to the recent studies, there are many simi-
larities and differences between EPCs and cancer cells
with regard to the Id1/PI3K/Akt/NFjB/survivin signal-
ling pathway. It is documented that the Id1/PI3K/Akt,
Fig. 6 Impact of Id1 on the
effects of CCN1, and p21. a Id1
expression in EPCs was down-
regulated by Ad-CCN1. The
values are expressed as the
mean ± SD.
#P\0.05 versus
control. b Cotransfection with
Ad-CCN1 decreased the
proliferation of EPCs. The
results are expressed as the
mean ± SD.
#P\0.05 versus
Ad-GFP; *P\0.05 versus Ad-
Id1. c, d The expression of p21
was decreased by over-
expression of Ad-mediated
exogenous Id1 and improved by
silencing of endogenous Id1 in
EPCs. The values are expressed
as the mean ± SD.
#P\0.05
versus control
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play important regulations both in EPCs and in cancer cells
proliferation [20, 22, 32, 33]. However, Id1, PI3K/Akt,
NFjB, and survivin are potentially up-regulated in a wide
variety of human cancer cells compared with normal EPCs.
Id1, PI3K/Akt, NFjB, and survivin may be candidate
genes for cellular survival of several types of cancer cells,
and the Id1/PI3K/Akt, PI3K/Akt/NFjB, and NFjB/survi-
vin signalling pathways are involved in many types of
cancer cells apoptosis resistance and survival [21]. Unlike
cancer cells or tissues, the basal expression of Id1, PI3K/
Akt, NFjB, and survivin in quiescent EPCs was barely
detectable. Our previous studies demonstrated that over-
expression of exogenous Id1 directly stimulated prolifera-
tion and migration of EPCs [18]. Additionally, the PI3K/
Akt and PI3K/Akt/NFjB signalling pathways play a piv-
otal role in the process of EPC mobilisation [32, 34],
migration, homing, and angiogenesis. But the relationship
between Id1, PI3K/Akt, and NFjB/survivin in the biolog-
ical function of EPCs is largely unknown at present.
Therefore, further studies will be required to determine
whether the Id1/PI3K/Akt/NFjB/survivin signalling path-
way is involved in regulating the biological functions of
EPCs.
In this study, we determined the effects of Id1/PI3K/
Akt/NFjB/survivin signalling on EPC proliferation using
western blot analysis and MTS assays. The present results
identiﬁed that Id1 induced the activation of the PI3K/Akt/
NFjB/survivin signalling pathway during EPC prolifera-
tion. The in vitro transfection of EPCs with Ad-Id1 induced
the phosphorylation of Akt via PI3K and increased the
expression of survivin via NFjB. Simultaneously, knock-
down of endogenous Id1 signiﬁcantly reduced the prolif-
eration of EPCs, and led to suppression of PI3K/Akt/
NFjB/survivin signalling pathway in EPCs. Therefore,
these evidences suggest that the proliﬁc property of EPCs
is attributable to the up-regulation of Id1, p-PI3K, p-Akt,
and survivin, as well as the nuclear translocation of NFjB/
p65. In addition, blockage of the PI3K/Akt/NFjB/survivin
signalling pathway by the PI3K inhibitor LY294002, the
Akt-speciﬁc inhibitor, the NFjB inhibitor BAY 11-7082,
the survivin inhibitor Curcumin, and the survivin inhibitor
YM155 abrogated Id1-induced EPC proliferation. Inter-
estingly, treatment with the NFjB inhibitor BAY 11-7082
signiﬁcantly decreased the nuclear translocation of NFjB
subunit p65 but did not affect PI3K/Akt activity. This
indicates that PI3K/Akt is upstream of NFjB. Treatment
with the survivin inhibitor Curcumin or YM155 signiﬁ-
cantly decreased the expression of survivin but did not
affect PI3K/Akt/NFjB activity. This ﬁnding indicates that
survivin is downstream of PI3K/Akt/NFjB. These ﬁnd-
ings, taken together, demonstrate the existence of an Id1/
PI3K/Akt/NFjB/survivin signalling pathway during EPC
proliferation.
In this study, we explored the effect of PI3K/Akt inhi-
bition on the Id1 expression in EPCs. Little is known about
the interaction between PI3K/Akt and Id1 in EPC prolif-
eration. We demonstrated that over-expression of exoge-
nous Id1 directly stimulated up-regulation of p-PI3K and
p-Akt and proliferation of EPCs. In this study, we showed
that Id1 and p-Akt were strongly decreased by PI3K/Akt
signalling inhibitor LY294002 in EPCs without exogenous
Id1 transfection. Interestingly, inhibition of PI3K/Akt
activity in Ad-Id1-transfected EPCs by LY294002 reduced
the expression of p-Akt only but not Id1. This is a novel
ﬁnding. Taken together, our data support the notion that
there is an important interaction between PI3K/Akt and
endogenous Id1 in EPCs, which might ensemble contribute
to the EPC proliferation.
Furthermore, we investigated whether Id1 is involved in
the expression of VEGF, CCN1, and p21 in EPCs. Several
reports revealed that Id1 is involved in the expression of
VEGF, p21, and CCN1, thereby regulating EPC prolifer-
ation and the re-endothelialisation [17, 19, 27, 35]. Our
study observed that transfection of Ad-Id1 into EPCs
increased the release of VEGF. It was intriguing to observe
such effect of Id, as VEGF are thought to be important
mediators of EPCs proliferation. However, Id1 was
induced by VEGF, which has been proven by our study. In
this study, our results showed that VEGF up-regulated Id1
in EPCs, and vice versa, strengthening the hypothesis that a
paracrine loop may exist between Id1 and VEGF that
regulates EPC proliferation. In this study, we found that
Id1 expression in EPCs was down-regulated by Ad-CCN1,
which is in accordance with our previous studies [27].
In addition, cotransfection with Ad-CCN1 decreased
the proliferation of EPCs. To date, the exact interaction
between CCN1 and Id1 in EPC proliferation remains elu-
sive and further studies are needed to make it clear. Pre-
vious studies have revealed that the restraint of p21
expression by Id1 is one key element of its activity in
facilitating the generation of EPCs [19]. Our present results
demonstrated that the expression of p21 was decreased
by over-expression of Ad-mediated exogenous Id1 and
improved by silencing of endogenous Id1 in EPCs. Taken
together, these results demonstrated that Id1 expression is
involved in the expression of VEGF, CCN1, and p21,
thereby regulating EPC proliferation in vitro.
However, this study has many limitations as follows: (1)
our observations were based on an in vitro experiment and
not an animal model of vascular injury, and thus, the
conclusions drawn may be limited to cell experiments; (2)
thus far, we do not know whether the up-regulation of
survivin can cause carcinoma in an animal model, and
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123the observation related to survivin was limited to in vitro
experiments.
In summary, we demonstrated that Id1 is a critical
regulator of EPC proliferation, and the Id1/PI3K/Akt/
NFjB/survivin signalling pathway may play an important
role during EPC proliferation. Id1, PI3K, Akt, NFjB,
and survivin may represent novel therapeutic targets for
re-endothelialisation after vascular injury.
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